Abstract
Therapeutic development for Alzheimers disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process. However, with the recent discovery of mutations that result as pathologic buildup of tau in the absence of amyloid pathology, tau is beginning to be recognized as a potential target for drug discovery. We have developed a high-throughput drug screening method that allows for direct intracellular quantitation of tau protein species, enabling the fast, reliable detection of these changes. We have identified a family of small, blood brain barrier penetrant heat shock protein 90 inhibitors that significantly reduce tau protein levels in vitro. Western blot analysis demonstrated a clear inverse correlation between the tau levels and the increase in HSP27, HSP40 and HSP90. Modifications to this assay will further allow the specific analysis of pathologically relevant species. Using this assay, we have demonstrated that a class of HSP90 inhibitors is able to significantly lower intracellular tau levels most likely through induction of a heat shock response.
Keywords: alzheimer, ’, s disease (ad), neurodegeneration, neurofibrillary tangles (nft), nmda receptor antagonist, amyloid precursor protein, tau knockout mice, expression
Current Alzheimer Research
Title: Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Volume: 2 Issue: 2
Author(s): Chad A. Dickey, Jason Eriksen, Adeela Kamal, Francis Burrows, Srinivas Kasibhatla, Christopher B. Eckman, Mike Hutton and Leonard Petrucelli
Affiliation:
Keywords: alzheimer, ’, s disease (ad), neurodegeneration, neurofibrillary tangles (nft), nmda receptor antagonist, amyloid precursor protein, tau knockout mice, expression
Abstract: Therapeutic development for Alzheimers disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process. However, with the recent discovery of mutations that result as pathologic buildup of tau in the absence of amyloid pathology, tau is beginning to be recognized as a potential target for drug discovery. We have developed a high-throughput drug screening method that allows for direct intracellular quantitation of tau protein species, enabling the fast, reliable detection of these changes. We have identified a family of small, blood brain barrier penetrant heat shock protein 90 inhibitors that significantly reduce tau protein levels in vitro. Western blot analysis demonstrated a clear inverse correlation between the tau levels and the increase in HSP27, HSP40 and HSP90. Modifications to this assay will further allow the specific analysis of pathologically relevant species. Using this assay, we have demonstrated that a class of HSP90 inhibitors is able to significantly lower intracellular tau levels most likely through induction of a heat shock response.
Export Options
About this article
Cite this article as:
Dickey A. Chad, Eriksen Jason, Kamal Adeela, Burrows Francis, Kasibhatla Srinivas, Eckman B. Christopher, Hutton Mike and Petrucelli Leonard, Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585927
DOI https://dx.doi.org/10.2174/1567205053585927 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment
Current Medicinal Chemistry Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Utilization of the DaT-SCAN SPECT in the Diagnosis of Parkinson's Disease in Older Subjects
Letters in Drug Design & Discovery Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Editorial : Novel Therapeutic Targets for Cardiovascular Disease
Current Pharmaceutical Design Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Patterns of Cognitive Impairment in Neurological Disease
Current Psychiatry Reviews Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets Converging Perturbed Microvasculature and Microglial Clusters Characterize Alzheimer Disease Brain
Current Alzheimer Research